Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...
Presentation Highlights As of the data cut-off date of September 30, 2024, 89 patients have been treated with IDRX-42 in the Phase1 portion of the ongoing StrateGIST 1 trial across dose cohorts ...
In a phase1 clinical trial, small groups of participants get a new drug, or a combination of several drugs, that has shown anti-cancer promise in test tubes and animals and is being tested for ...
--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase1 study of nucresiran ...